Rennova Health, Inc. announced the formation of a Scientific Advisory Committee. The Committee, which was appointed by the company's board of directors, is comprised of Chairman Thomas Mendolia, D.O., George Lundberg, M.D., Bernard Manz, Ph.D., Georg Manz, Paul Billings, M.D., Kamran Ajami, M.D., Christopher Mason, Ph.D. and Asad Zaidi. Dr. Mendolia is a retired gastroenterologist and co-founder of Medytox Solutions, Inc. He was in clinical practice for 29 years, including 17 years in private practice at Tri-County Gastroenterology in Elkin, N.C. Dr. Lundberg is president and chair of the board of directors of The Lundberg Institute, a consulting professor at Stanford University and editor-at-large for Medscape from WebMD.

He served as president of the American Society for Clinical Pathology, professor of pathology and associate director of laboratories at the Los Angeles County/USC Medical Center for 10 years, and was the professor and chair of pathology at the University of California, Davis for five years. Bernhard Manz, Ph.D., LDN developed DrySpot, the first urinary spot test for neurotransmitters six years ago. Georg Manz has a background in immunology and immunoassay development.

He worked with Dr. Bernhard Manz on the development and the implementation of the DrySpot technology. Since 2012 Georg has been general manager of Labor Diagnostika Nord (LDN), and since 2015 has served as CEO of Rocky Mountain Diagnostics. Dr. Billings is a nationally recognized author, lecturer, consultant, professor and thought leader in the field of genomic medicine and has served as a director of CollabRx, Inc. since 2014.

A board-certified internist and clinical geneticist, Dr. Billings' career has been devoted to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as chief medical officer of Life Technologies, Inc. Dr. Billings currently serves on the Scientific Advisory Board of the U.S. Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Dr. Kamran Ajami is a surgical pathologist with sub-specialties in gynecology, breast pathology and neuropathology. He has 22 years of experience in cancer diagnosis and moved from an academic position at Harvard Medical School to his current position serving as the market lead of South Florida's division of HCA hospitals and chairman and medical director of Westside Regional Medical Center and Plantation General Hospital.

Dr. Ajami serves as the CEO of Cytopathology Associates. Dr. Christopher Mason is an associate professor of computational genomics and neuroscience in the department of physiology and biophysics at the Feil Family Brain and Mind Research Institute, and the Institute for Computational Biomedicine at Weill Cornell Medical College in New York City. Asad R. Zaidi, president and CEO of Epinex Diagnostics, Inc., is a biochemist and biomedical engineer.